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ABSTRACT 
OA1 (GPCR143), the protein product of the ocular albinism type 1 gene, encodes 
a pigment-cell specific G Protein-Coupled Receptor (GPCR) that localizes 
intracellularly to melanosomes. OA1 mutations result in ocular albinism due to 
alterations in melanosome formation, suggesting that OA1 is a key player in the 
biogenesis of melanosomes. To address the function of OA1 in melanosome 
biogenesis we have used siRNA inactivation and combined morphological and 
biochemical methods to investigate melanosome ultrastructure, melanosomal protein 
localization and expression in human pigmented melanocytic cells. OA1 loss of 
function leads to decreased pigmentation and causes formation of enlarged aberrant 
premelanosomes harboring disorganized fibrillar structures and displaying proteins of 
mature melanosomes and lysosomes at their membrane. Moreover we show that 
OA1 interacts biochemically with the premelanosomal protein MART-1. Inactivation 
of MART-1 by siRNA leads to a decreased stability of OA1 and is accompanied by 
similar defects in premelanosome biogenesis and composition. These data show for 
the first time that melanosome composition and identity are regulated at early stages 
by OA1 and that MART-1 likely acts as an escort protein for this GPCR.  
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Introduction  
Albinism comprises a heterogeneous group of inherited genetic disorders 
characterized by a variable loss of pigmentation in the eye, hair or skin. Ocular 
albinism type 1 (OA1) is an X-linked disorder that, differently from other forms of 
albinisms, is not caused by impairment of melanin production but by reduced 
number of melanosomes (1), the organelles in which melanin is synthesized and 
stored in Retinal Pigment Epithelium (RPE) and skin melanocytes.  Mutations in OA1 
gene also induce formation of aberrant “giant” melanosomes, called 
macromelanosomes (2). Thus, this form of albinism appears to be caused by a 
defect in melanosome organellogenesis. The protein product of the OA1 gene is a 
pigment cell specific G protein-coupled receptor (GPCR) (3-6). Differently to 
canonical GPCR, OA1 preferentially localizes to intracellular compartments such as 
melanosomes and lysosomes where it can signal from the organelle lumen to the 
cytosol (4, 7). Although the genetic defect was reported more than 10 years ago (8), 
how OA1 functions to control melanosome biogenesis has remained enigmatic, 
frustrating efforts toward development of new therapeutic strategies for ocular 
albinism.  
Melanosomes are lysosome-related organelles that are distinct from conventional 
lysosomes within pigment cells (9, 10). Melanosomes develop through sequential 
maturation stages that can be defined based on morphology and that are enriched in 
a specific set of protein components (9, 11). Stage I and II melanosomes are 
characterized by the presence of intralumenal fibrillar sheets (12-14), in which the 
major component is the fibrillogenic protein Pm l17 (13, 15-17), but lack 
melanogenic enzymes such as Tyrosinase and Tyrosinase-related proteins. 
Deposition of black melanin along the fibers is initiated in stage III melanosomes as 
a consequence of the delivery of melanogenic enzymes to preformed stage II 
melanosomes. Once formed, the mature stage IV melanosomes are transported to 
the cell periphery for transfer to neighboring keratinocytes or stored within ocular 
melanocytes in the retinal pigment epithelium (18, 19).  
Stage I premelanosomes correspond to early endosomal vacuoles that serve 
as intermediates for cargo bound both for lysosomes and melanosomes at different 
stages.  As a first step towards melanosome formation, the transmembrane protein 
Pmel17 is sorted to intraluminal vesicles (ILVs) of endosomes thereafter called 
multivesicular bodies (MVBs) (9, 15, 16). Concomitant with the sequestration in ILVs, 
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Pmel17 is cleaved by a prohormone convertase liberating a fibrillogenic fragment 
(Mα) in its lumenal domain which leads to the generation of the non-membranous 
amyloid like fibrillar structures (14, 16, 20). Whereas sorting of Pmel17 appears to be 
independent of ubiquitylation and of the (Endosomal Sorting Complex Required for 
Transport) ESCRT-0/ESCRT-I machinery (21), sorting of another melanosomal 
protein, MART-1 that is similarly sequestered in ILVs of MVBs, appears to require 
ubiquitylation (22, 23) and ESCRT proteins (21, 24). MART-1 has been reported to 
interact with Pmel17 (25), but the function of MART-1 in melanogenesis is not well 
understood.  
In this study, we investigated the role of OA1 in melanosome biogenesis 
addressing its intracellular localization and how loss of function may alter trafficking 
steps required for melanosome maturation. In addition we investigated how it may 
exert its role together with other melanosomal proteins. Using a combination of light 
and electron microscopy and biochemical methods we show that OA1 controls the 
generation of premelanosomes and that it cooperates with MART-1 for this function. 
Altogether our data suggest that OA1 functions together with MART-1 to maintain 
melanosome composition and identity within the endocytic system.  
 
 
Results 
OA1 localizes to immature and mature melanosomes 
Previous studies have addressed the subcellular localization of endogenous OA1 or 
GFP-tagged recombinant OA1 in melanocytic cells (4, 7, 26), but its localization 
within the distinct melanosomal stages and/or endosomes and lysosomes was not 
completely resolved. To qualitatively and quantitatively evaluate the subcellular 
distribution of the endogeneous OA1 protein in the melanocytic cell line MNT-1 we 
have used immunogold labeling on ultrathin cryosections (IEM). MNT-1 cells 
resemble untransformed skin melanocytes by expression of mRNAs encoding 
melanogenic proteins (27) and by ultrastructure, presenting melanosomes at all four 
stages (9). We have also investigated the localization of recombinant OA1 protein 
(OA1-Flag or OA1-EGFP) in transfected MNT1 cells (see below, fig S1) and in mouse 
melan-a immortalized melanocytes (data not shown). Consistent with previous 
studies, OA1 was detected at the limiting membrane of a small cohort of pigmented 
melanosomes labeled for the melanosomal enzyme Tyrp1 (stage III-IV) (fig 1A, 
arrows).  Within these mature pigmented melanosomes, OA1 was often associated 
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with small intraluminal vesicles (arrowhead fig 1A) and was also present at the 
membrane of cytoplasmic vesicles often located in close proximity to melanosomes 
(fig 1B, arrowhead). OA1 was detected at the limiting membrane of lysosomes (fig 
1E, arrows) and in intraluminal vesicles of late endosomes/Multivesicular Bodies 
(MVBs) (fig 1E, arrowheads). In agreement with its association with ILVs of MVBs, 
like other ILV associated membrane proteins such as CD63, OA1 was detected in 
extracellular exosomes secreted from MNT-1 after 48h of culture (not shown). 
Although OA1 appeared broadly distributed, our observations revealed that the bulk 
of OA1 was localized to organelles highly labeled for Pmel17 (fig 1C, 1D, arrows; see 
quantification in fig 1F) that correspond to stage I and stage II premelanosomes (9). 
This is consistent with but extends quantitatively the observations reported 
previously (3) and (7). Similarly to endogenous OA1, the recombinant transfected 
proteins (OA1-Flag or OA1-EGFP) localize to the distinct melanosomal stages and to 
lysosomes. However, as compared to the endogenous protein we observed a shift in 
the localization of OA1 towards more mature melanosomes (fig S1A, S1B, arrows). 
We also observed that cells expressing higher levels of OA1 were characterized by 
the presence of large electron-lucent OA1 positive membrane vesicles (350 nm). 
These vesicular structures were also labeled for Tyrp1, and often localized in close 
proximity to melanosomes in both human (fig S1A, asterisks) and mouse cells (data 
not shown). These vesicles were possibly induced by the overexpression of OA1 
since they were not observed in Flag/EGFP empty vectors transfected cells (data not 
shown). The observed phenotype indicates that the trafficking of recombinant OA1 
may not fully reflect that of the endogenous protein. However, on the other hand it 
also suggests a dominant negative effect of OA1 expression that maybe result in the 
accumulation of transport intermediates whose trafficking may be controlled by OA1.   
Altogether these data show that OA1 is widely distributed throughout the 
endo-melanosomal system but that most of endogenous protein is localized in 
unpigmented Stage II melanosomes. This finding is in agreement with the suggested 
function for OA1 at early stages of melanogenesis as we previously proposed (1). 
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OA1 loss of function affects melanosomal protein trafficking and 
melanosome size at early stages of biogenesis  
To get further insights on the function of OA1, we inactivated OA1 by RNAi in 
pigmented MNT1 cells and analyzed melanosome morphology and composition right 
after the loss of OA1 activity. This approach overcomes the limits and/or 
compensations of immortalized melanocytes from OA1 patients or mice that contain 
primarily mature organelles and preclude the study of the different sequential events 
leading to the formation of macromelanosomes.  
We designed and tested three oligonucleotides targeting three different regions of 
the human OA1 mRNA. As a control we have used a non-targeting siRNA. One of the 
three siRNAs (siRNA #3) was very efficient in reducing the levels of OA1 transcripts 
(15% siRNA #1, 78% siRNA #2, 95% siRNA #3)(fig 2A) and was used for 
experiments presented here. Downregulation of endogenous OA1 protein was 
confirmed by WB and IF (fig 2B-D). We found that mature melanosomes and 
melanin content in siOA1 MNT1 cells were reduced as much as 50% compared to the 
cells treated with the control siRNA (fig 2E-G). Analysis at the ultrastructural level, by 
conventional EM, also showed a reduction of the total number of melanosomes in 
MNT1 cells depleted of OA1 (fig 2H-K), consistent with the phenotype characterized 
in ocular albinism mouse model and patients. Although we did not observe the 
“classical” pigmented macromelanosomes, we found that OA1 depleted MNT1 cells 
harbor abnormally enlarged organelles with a heterogeneous content that are mixed 
with normal melanosomes and could possibly correspond to the precursors of the 
macromelanosomes (fig 2I; fig S2A). These aberrant mixed compartments contains 
Pmel17 positive fibrils characteristic of immature melanosomes and an electron 
dense core of melanin (fig 2I, asterisk; fig S2B-C). Similar phenotypes were observed 
with a second siRNA sequence (siRNA #2) excluding that the phenotype derives from 
mistargeting. Of note, similar enlarged “mixed” organelles were also observed in OA1 
in vitro cultured melanocytes from knockout mouse (melan-Oa1-/-) (fig S2D-E). Cells 
depleted of OA1 also harbored enlarged immature unpigmented melanosomes that 
had lost the typical striated appearance and whose internal fibrils were clearly 
disorganized (fig 2I, arrowhead; fig S2A; fig 3B, 3D, 3F).  In order to investigate if 
these morphological alterations were accompanied by a defect in the localization of 
melanosomal proteins, we analyzed the distribution of melanosomal proteins in  OA1 
depleted MNT1 cells by IEM. The fibrillar structures apposed to or contained within 
the abnormal melanosomal structures were highly labeled with an antibody directed 
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against Pmel17, the major component of the fibrils (fig 3B, arrowhead; fig S2C, 
arrows). Of note, Tyrp1 that is nearly absent from Pmel17 enriched Stage II 
premelanosomes in control cells, is detected at high levels at the membrane of the 
enlarged organelles (fig 3A-B, arrows, see also fig 3F) suggesting an alteration of its 
trafficking upon OA1 depletion. Another protein that appeared to be mislocalized to 
the enlarged melanosomal organelles is LAMP-1. LAMP-1 is a lysosomal protein that 
is present only in small amounts at the membrane of Tyrp1 positive melanosomes 
((9) and fig 3C, 3E, arrows). In OA1 depleted cells LAMP1 was abundant in both 
aberrant enlarged pigmented organelles and normal size melanosomes (fig 3D, 3F, 
3G, arrows). Quantification of these observations is shown in Table 1. LAMP1 also 
accumulated in Tyrp1 positive vacuolar structures (fig 3H, inset) that were 
reminiscent of the vesicles observed upon OA1-Flag overexpression (fig S1) 
suggesting that depletion of OA1 or a dominant negative effect may lead to similar 
phenotypes. It also suggests that OA1 may function at a fusion/fission step 
regulating Tyrp1 and LAMP1 content of melanosomes. Although the melanin content 
was generally reduced in siOA1 MNT1 cells, western blot experiments performed in 
these cells revealed a slight increase of the amount of Tyrp1 in the OA1 depleted 
cells and no significant differences in the amount of LAMP1 (fig 3I), consistent with a 
defect in their trafficking and not expression/degradation. To get further insight on 
the trafficking defects and nature of the organelles affected upon OA1 loss of 
function, we performed IEM on cells that were allowed to internalize Transferrin 
(early-recycling endosomes), BSA-gold (endo-lysosomal compartments) or that were 
incubated with the weak base DAMP, to evaluate the acidity of the organelles (9). 
Transferrin (data not shown) and the endocytic tracer BSA-gold (BSAG) were not 
detected in the enlarged organelles (fig S3A-B) and vacuoles (data not shown) 
indicating that the defects in trafficking and organelle biogenesis caused by OA1 loss 
of function were not due to aberrant mistargeting within the endosomal system. The 
enlarged melanosomal organelles appeared to acidic as are premelanosomes in wild 
type cells as assayed with DAMP (9) (fig S3C-D). However, and despite that DAMP 
accumulation is not a quantitative assay for pH, these organelles show an increased 
labeling for the radical DNP (fig S3D), suggesting that they may be slightly more 
acidic.  
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OA1 and MART-1 loss of function similarly affect Pmel17 final processing 
and early melanosome biogenesis. 
We next aimed at further investigating how premelanosome biogenesis could be 
affected by the loss of OA1 function. The major biogenetic component of the stage II 
fibrils is the pigment cell-specific protein Pmel17. In stage II melanosomes the 
Pmel17 forms are detectable with HMB45 antibody, which recognizes the Mα 
fragment and its proteolytic products (28-30) and with Pep13h antibody, recognizing 
the processed full length (P1, 100kD) and the cleaved forms (Mβ, 26kD and CTF, 
10kD) (31).  
Enlarged organelles displayed disorganized fibrils and this prompted us to evaluate 
Pmel17 expression and processing. We did not detect significant changes of Pmel17 
transcript levels upon OA1 loss of function (fig S4A). Next we analyzed the different 
maturation forms of Pmel17 by using HMB45 and Pep13h antibodies. Although 
Pep13h did not reveal significant differences in the levels of P1 and Mβ (fig 4Ac), an 
accumulation of Mα fragment (80kD) and a reduction of one of its products (MαC, 
35kD) was observed with the HMB45 antibody in both the TX-soluble (fig 4Aa) and 
TX-insoluble pool (fig 4Ab) of siOA1 cell lysates (fig 4A). The TX-insoluble pool is 
enriched in amyloid fibers that are insoluble in non-denaturing detergent TX100 (16). 
Since MαC is considered to be the major form of the HMB45-reactive species within 
the fibers (29, 30) its reduction is likely to reflect the disorganization of amyloid-like 
fibers observed in stage II melanosomes in siOA1 MNT1 cells (fig 2I, arrowhead; fig 
3D, 3F). These results indicate that although Pmel17 appears to be cleaved in its 
luminal domain, its final processing to form the MαC fragment is impaired consistent 
with the altered morphology of the intraluminal contents of the premelanosomal 
compartment. 
 Such effects observed upon OA1 depletion were reminiscent of those described in 
cells that do not express MART-1 (25). MART-1 is an integral membrane 
melanosomal protein that has been shown to form complexes with Pmel17 and has 
been suggested to control Pmel17 processing and stability (25). We therefore used 
siRNA to deplete MART-1 from MNT-1 cells. MART-1 was effectively downregulated 
(reduction of 90% of detectable MART-1 transcript and protein) (fig 6I and fig 4B). 
We confirmed that Pmel17 maturation was affected in MART-1 depleted cells and in 
particular, similarly to OA1 knockdown, we detected accumulation of the Mα 
fibrillogenic fragment accompanied by a reduction of its subproduct MαC (fig 4B). To 
better define the compartments affected by MART-1 depletion, we performed 
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immunogold EM analysis on ultrathin cryosections of siMART-1 MNT1 cells. No 
normal stage I premelanosomes were found, but we noted the presence of many 
aberrant enlarged compartments that often appeared as a mixture of striations and 
electron dense pigment, similar to those observed in siOA1 cells (fig 4D). 
Interestingly, these compartments contained abnormally large intraluminal vesicles 
and their Pmel17-positive fibers were disorganized and/or apposed to one or both 
sides, indicating altered early melanogenesis. We also found that Tyrp1 (fig 4E, 4F, 
arrows), and LAMP1 (data not shown) accumulated in early Pmel17 positive 
premelanosomal compartments with concomitant reduction at the melanosomal 
membrane as compared with the control cells.  
Overall these observations show that loss of function of either OA1 or MART-1 leads 
to an impairment of melanosome biogenesis at its earliest steps and to mis-
trafficking of distinct melanosomal proteins likely en route to their final destination, 
in this case lysosomes or melanosomes. Moreover these results show that MART-1, 
similarly to OA1, regulates melanosome maturation and in particular the 
maintenance of melanosomal identity and composition.   
 
MART-1 interacts with OA1 and is required for OA1 stability in MNT1 cells  
Based on the data presented so far we hypothesize that either OA1 and MART-1 
fulfill a similar redundant function in early melanogenesis or that one of the two 
proteins affects the function of the other. We thereby evaluated possible interactions 
between these proteins and investigated the consequences of MART-1 loss of 
function on OA1 expression and localization.   
For this purpose, we immunoprecipitated endogenous OA1 from MNT1 extracts and 
tested for the presence of MART-1 by immunoblotting.  Consistent with our 
hypothesis, the 18kDa form of MART-1, corresponding to the not-ubiquitylated form 
(23), was detected in the anti-OA1 immunocomplexes (fig 5A). We confirmed the 
specificity of this interaction by co-immunoprecipitation of OA1 with Galpha-i3 (data 
not shown), as already published (4), but not with the melanogenic enzyme Tyrp1 
(fig 5A). Although we detected a biochemical interaction between OA1 and MART-1, 
co-localization, as analyzed by immunofluorescence followed by 3D deconvolution or 
IEM, was limited to only a small subset of cellular compartments (fig 5B-L). OA1 was 
distributed in vesicular structures that mainly correspond to immature and mature 
melanosomes (see also Fig.1), but MART-1 was essentially localized in the 
perinuclear area in a region that mainly corresponds to the Golgi/TGN and post-Golgi 
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endosomal compartments (fig 5B-I and 5J). These data were confirmed by IEM, in 
which OA1 and MART-1 were detected together only within the Golgi, vesicles close 
to the Golgi apparatus and endosomal compartments (fig 5J, 5K,5L, arrows).  
Interestingly, when we analyzed cell lysates from cells in which MART-1 was 
depleted with siRNA, we found that MART-1 depletion greatly affected OA1 protein 
expression and distribution, reducing the levels of OA1 protein (fig 6E-H, 6J) but not 
its transcript (fig 6I). By contrast, MART-1 RNA and protein levels were not affected 
in the absence of OA1 (fig S4A-B).  These observations suggested that MART-1 loss 
of function induces an increased degradation of OA1. To further test this hypothesis 
and to investigate the mechanisms involved in its decreased expression/stability, 
MART-1 depleted cells were treated for 5 hrs with drugs known to inhibit lysosomal 
(chloroquine) or proteasomal degradation (MG132 or epoxomycin) respectively. 
Chloroquine is an inhibitor of intra-lysosome catabolism that raises intralysosomal pH 
disrupting the activity of lysosomal acid hydrolases (32) (33). As analyzed by western 
blot, in control cells treated with Chloroquine, the levels of OA1 increased after 5hrs 
of treatment, showing that OA1 generally undergoes a lysosomal degradation. A 
similar increase of OA1 protein levels was observed in Chloroquine-treated MART-1-
depleted cells (fig 6Ka), showing a partial rescue of OA1 protein levels after only 5 
hrs of treatment. In order to address whether the proteasome was involved in OA1 
degradation, MART-1 depleted cells were then treated with two proteasome 
inhibitors MG132 or Epoxomycin. MG132 is a widely used potent synthetic inhibitor 
of a number of proteasome-associated proteases (34) (35). Epoxomycin is a natural 
proteasome inhibitor highly specific for the 20S proteasome (36). OA1 protein levels 
did not significantly change in treated versus untreated control cells. On the other 
hand, in siMART-1 MNT1 cells we observed significantly higher levels of OA1 protein 
after 5 hrs of incubation with proteasome inhibitors as compared to the siMART1 
untreated cells (fig 6Kb-c). These results suggest that, in absence of MART-1, OA1 is 
likely to follow also a distinct degradation pathway and in particular proteasomal 
degradation. The stronger effect of MG132 as compared to epoxomycin could be due 
to the fact that this compound is not specific for proteasome and is also a potent 
inhibitor of various cysteine proteases and cathepsins (37, 38). Overall, these data 
show that OA1 stability/expression requires MART-1.  
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Discussion 
 
 Melanosomes represent a class of lysosome-related organelles that coexist with 
late endosomes and lysosomes within melanocytes and retinal pigment epithelium. 
The pathways by which melanosomal proteins are diverted from the classical 
endocytic organelles toward melanosomes and/or differentially targeted to different 
melanosomal stages are incompletely defined, but are disrupted in several genetic 
diseases (39). These diseases, leading to defects in melanosome biogenesis and 
transfer, are due to mutations in genes encoding proteins involved in intracellular 
trafficking but also mutations in melanosome specific proteins whose functions 
remain so far unclear (10, 39). We show here that the OA1 functions early in 
melanosome biogenesis controlling not only melanosome size but also melanosome 
composition, and thereby appropriate maturation. In addition we show that OA1 
stability and function is ensured by its interaction with the premelanosomal protein 
MART-1 assigning a significant role to this protein in melanosome biogenesis. 
 
OA1 functions in early melanogenesis and melanosome composition 
Our studies evidence that the bulk of intracellular OA1 localizes to Pmel17-
positive unpigmented premelanosomes. The presence of endogenous OA1 in the 
precursors of premelanosomes that also display other melanosomal proteins such as 
Pmel17 and MART-1 (9, 22, 40), suggest a function for this GPCR early in 
melanogenesis as previously predicted based in our genetic studies (1).  
The albinism phenotype caused by OA1 loss of function is characterized not 
only by the presence of macromelanosomes but also by a reduction in melanin 
content and the number of melanosomes at early stages of their maturation (1, 41). 
After 5 days of OA1 inactivation we were able to reproduce the defect in 
melanosome number but not the “classical” macromelanosome phenotype probably 
because a longer time is required to complete melanosome maturation. However 
even after short inactivation (3 to 5 days) we observed abnormal enlarged 
pigmented structures with a heterogeneous content. These structures display a size 
similar to macromelanosomes with an average diameter of 0,9-1 µm (1). In addition, 
several of the enlarged compartments observed in OA1 knocked-down cells, 
although not fully electron dense like macromelanosomes in melanocytes from OA1 
mutant mice, display a mixed content with an “amorphous” melanin core and fibrillar 
sheets ((2) and fig S2B-E.). For all these reasons we believe that the enlarged 
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structures observed in si-OA1 cells correspond to the precursors of 
macromelanosomes. These aberrant compartments could result from fusion of 
anomalous premelanosomes with mature melanosomes. Otherwise and not mutually 
exclusive, these compartments could also arise from an improper 
formation/composition of immature Stage II melanosomes resulting from abnormal 
fusion of transport intermediates – or from lack of retrograde transport from 
maturing melanosomes – to remove cargoes like LAMP1. This is supported by our 
observations that OA1 depleted cells accumulate Tyrp1 containing vesicular 
structures and that immature melanosomes (stage I-II) displayed consistent 
amounts of Tyrp1 at their limiting and internal membranes. This melanogenic 
enzyme is in general absent from Stage I/Stage II unpigmented melanosomes and 
enriched in pigmented Stage III and Stage IV (9). These observations indicate 
mistargeting of melanogenic enzymes to immature melanosomes and this event may 
lead to abnormal pigment synthesis within premelanosomal compartments. These 
observations can also explain the reduced number of early stage melanosomes 
observed in OA1 mutant RPE (1). Abnormal protein targeting is not limited to 
melanogenic enzymes but also to proteins of other cellular organelles such as the 
lysosomal membrane protein LAMP1. LAMP1 is normally present in lysosomes, it is 
also detectable at lower amounts in mature melanosomes but absent from immature 
unpigmented melanosomes (9). The presence of Tyrp1 and LAMP1 in vesicular 
structures and within Pmel17 positive early melanosomes favors the hypothesis of an 
“aberrant” fusion of LAMP1 and Tyrp1 loaded vesicles with StageI/Stage II 
premelanosomes. The nature of the Tyrp1/LAMP1 containing transport intermediates 
is not totally clear but based on our recent studies they most likely correspond to 
post Golgi endosomal compartments (24). These studies indicate that endosomes are 
required intermediates for Tyrp1 transport from the Golgi to the limiting membrane 
of melanosomes. These endosomal domains are distinct from EEA1 positive early 
sorting endosomes and appear to be located just downstream of early recycling 
endosomes as in the absence of functional Tsg101 there is a reduced flux of Tyrp1 
via the plasma membrane and accumulation of Tyrp1 in endosomal vacuoles that are 
also positive for LAMP1 (24) and CD63 (data not shown). The vacuolar structures 
observed upon OA1 inactivation show similar characteristics, containing both Tyrp1 
and LAMP1 but not internalized Transferrin (data not shown) or the endocytic tracer 
BSAG, consistent with the notion that these are post-Golgi/endosomal intermediates 
that are placed downstream of the sorting decision point to segregate endosomal 
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from melanosomal cargo. Similar vesicular structures bearing OA1 at their membrane 
were observed in OA1 overexpressing cells supporting our hypothesis that OA1 is 
involved in regulating trafficking of such intermediates. One plausible hypothesis is 
that OA1 controls their transport/fusion to/with melanosomes. Since we detected the 
bulk of endogeneous OA1 in immature melanosomes, OA1 possibly functions in 
these compartments to negatively control a “too early” fusion of transport 
intermediates before complete maturation of Stage II premelanosomes. In the 
absence of functional OA1 these transport intermediates aberrantly fuse with 
immature melanosomal compartments leading to mistargeting of these proteins to 
their membranes before completion of maturation. Thereby it seems plausible that in 
melanocytes issued from OA1 mutant mice, pigmented melanosomes rather 
correspond to immature aberrant organelles, with an inappropriate composition 
leading to synthesis of melanin pigments in the wrong organelle. This explains the 
morphological features of melanosomes and macromelanosomes in OA1 mutant cells 
and maybe underlies the transport defects of melanosomes recently reported in 
these cells (42).    
 
OA1 and MART-1 similarly influence Pmel17 processing and melanosome 
maturation 
The enlarged premelanosomal compartments harboring Tyrp1 and LAMP1 at 
their limiting membrane display Pmel17 positive fibrils in their lumen although the 
fibrils do not appear to be fully organized as in classical Stage II premelanosomes. 
The premelanosomal protein Pmel17 is properly processed as judged by western 
blotting and is able to generate fibrils indicating that its cleavage by prohormone 
convertases is not affected in the absence of functional OA1. However we observed 
an increased amount of the Mα fragment over MαC indicating that one very last step 
of its processing required for fibril formation is impaired resulting in abnormally 
assembled fibrils. The cause of the observed alterations in fibril 
formation/organization remains unclear. The intralumenal acidification of the 
aberrant organelles, as assayed with the weak base DAMP, does not appear to be 
significantly altered as compared to control unpigmented premelanosomes. 
Although, we cannot exclude that the slightly higher labeling observed in the 
inactivated cells could be due to a defective deacidification required to progress the 
fibrils and consequently mature melanosomes. Otherwise, the inefficient processing 
could also be the consequence of an altered trafficking of the enzymes required for 
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these last steps of Pmel17 processing. Confirming this hypothesis is difficult at the 
moment because, although some of the enzymes involved in early steps of Pmel17 
processing have been at least partially identified (16, 31), those allowing these final 
steps of cleavage are still unknown.  
Interestingly, a similar alteration of Pmel17 processing was observed in cells 
in which the premelanosomal protein MART-1 was inactivated. MART-1 has been 
suggested to control Pmel17 expression, stability, trafficking and processing (25). We 
show here that in cells in which MART-1 expression was reduced by 90%, Pmel17 
processing is affected but not its expression and trafficking. MNT1 cells show only a 
partial phenotype of that observed in primary human melanocytes and SK-MEL-28 
cells (25), however we confirmed MART1 functional relevance in the generation of 
Pmel17 Mα fragment. In this study we also unraveled a morphological phenotype in 
MART-1 knocked-down cells: enlarged aberrant premelanosomes with disorganized 
fibrils and mistargeting of Tyrp1 and LAMP1 to Pmel17 positive organelles. These 
vesicles are similar to those observed in OA1 depleted cells. Moreover and despite 
the higher enrichment in premelanosomes, OA1 such as the premelanosomal protein 
MART-1 is broadly distributed throughout the biosynthetic pathway, mature 
melanosomes and lysosomes. Interestingly, the ubiquitylation deficient mutant 
MART-1 is mistargeted to mature melanosomes (23) in a manner similar to the 
overexpressed OA1 in human and mouse melanocytes (our study). We therefore 
hypothesized that OA1 and MART-1 could function at a similar step and/or 
reciprocally regulate each other. 
 
OA1 expression and function requires MART-1 as an escort protein. 
 Our observations are consistent with the hypothesis that MART-1 is an 
essential regulator of OA1 expression and function. These two proteins interact 
biochemically, as shown by co-immunoprecipitation, and this interaction appears to 
be independent of the reported MART-1/Pmel17 interaction (25) since we did not 
observed co-immunoprecipitation of OA1 with Pmel17 (data not shown).  MART-1 
probably functions in the biosynthetic transport/stabilization of OA1 and this 
indicates that the phenotypes observed in MART1 depleted cells could rather be the 
consequence of a decreased expression/function of OA1. In the absence of OA1 
MART-1 expression was not affected at the RNA and protein levels. In absence of 
functional MART-1, OA1 expression was not affected at the RNA level but 
significantly decreased at the protein level as assayed by western blot and 
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immunofluorescence.  We have also shown that in absence of MART-1 OA1 appears 
to be degraded by a lysosomal pathway involving the ubiquitin/proteasome system. 
Consistent with this hypothesis, OA1 expression is restored in cells depleted for both 
MART-1 and Tsg101, a component of the ESCRT machinery involved in degradation 
of ubiquitinated cargo proteins (data not shown). These observations show for the 
first time that OA1 can be degraded by Lysosomal/proteasomal degradation similarly 
to other GPCRs (43, 44). In addition we showed that MART-1 can interact with OA1 
early during its biosynthetic pathway acting as an escort protein that helps its 
stabilization to prevent degradation. Innamorati et al. showed that arrestin induces 
an accelerated degradation of OA1 in transfected cells (5) and it is commonly 
accepted that arrestins can directly induce GPCR degradation by a process distinct 
from internalization i.e. by promoting receptor ubiquitination through recruitment of 
E3 ligases and subsequent lysosomal and/or proteasomal-mediated destruction (45, 
46). Future studies are needed to unravel the relationship of OA1 interaction with 
MART-1, arrestin and the ESCRT machinery in the regulation of its degradation.  
 In conclusion, we show that the GPCR OA1 functions in early melanogenesis 
controlling melanosome size and composition that impacts on their identity and 
consequent maturation. In addition we evidence that OA1 expression is ensured by 
its interaction with MART-1 revealing a role for this protein in melanosome 
biogenesis. Altogether our data sheds light on how OA1 regulates key steps of 
melanosome formation also unraveling pathways by which melanosomal proteins are 
diverted from the classical endocytic organelles and/or differentially targeted to 
different melanosomal stages. These studies have important implications for 
understanding the pathophysiology of OA1, the involvement of GPCRs in intracellular 
trafficking and how highly specialized cells exploit intracellular trafficking pathways to 
generate unique organelles.  
 
 
 
 
 
 
 
 
Materials and methods 
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Cell culture, transfection and siRNA depletion 
The immortalized Oa1 null (melan-Oa1-/-). and wild type melanocytic cell lines 
were derived from wild type or Oa1-/- mouse skin (42)  and maintained in RPMI-1640 
supplemented with 10%FCS and 200nM phorbol 12-myristate 13-acetate at 37°C 
with 10% CO2. MNT-1 human melanoma cells were maintained as previously 
described (9). MNT-1, melan-O and melan-a were transfected with plasmid 
constructs using Lipofectamine 2000 (Invitrogen) following manufacturer’s 
recommendations. Cells were collected and analyzed after 48 h. Transfection in 
MNT-1 with siRNA duplex oligonucleotides proceeded as reported (21) and according 
to the manufacturer’s instructions. Cells were subjected to two rounds of transfection 
(day 0 and day 2), were passaged as required, and processed at day 3 or day 5 for 
real time qPCR, immunofluorescence microscopy, electron microscopy, western 
blotting and melanin assay. 
The sense strands for the indicated double stranded siRNAs (21-mers) were 
synthesized with the following sequences or derived from the following references.  
siRNA OA1 #1: 5’- GGA TAT GAA CCA CAC GGA A -3’ (Hs_GPR143_6_HP siRNA from 
QIAGEN); siRNA OA1 #2: 5’- GGC TGT AAA GTA AGT GTA A -3’ (Hs_GPR143_3_HP 
siRNA from QIAGEN); siRNA OA1 #3: 5’- GGT TGT CGA ATA TCA TCA A -3’ 
(Hs_GPR143_1_HP siRNA from QIAGEN);  siRNA MART-1 #1: 5’- AAG ACG AAA TGG 
ATA CAG AGC -3’ (25); siRNA MART-1 #2: 5’- TCC GCT AGC AGT ACT AAT CAT -3’ 
(Hs_MLANA_7_HP from QIAGEN); . siRNA non-targeting control: 5’- AAT TCT CCG 
AAC GTG TCA CGT -3’.  
Reagents and Antibodies 
Primary antibodies: polyclonal anti-human OA1, raised against the C-terminus 
of the human OA1, similar to the previously published (4); polyclonal anti EGFP 
(Molecular Probes); monoclonal anti flag M2 antibody (SIGMA-Aldrich); polyclonal 
anti flag (SIGMA-Aldrich); monoclonal anti β-tubulin antibody (SIGMA-Aldrich); TA99 
mouse anti-TYRP11 mAb (American Type Culture Collection; (47)) for 
immunofluoscence and immunogold labelling and monoclonal anti-Tyrp1 75kDa 
(Abcam) for western blotting; melanoma Ab-2 anti-Pmel17 (clone HMB50) (Lab 
Vision Corporation); mouse monoclonal anti-Pmel17 (clone HMB45) (Novocasta); 
Pep13h antibody was a kind gift from M.S.Marks (University of Pennsylvania, 
Philadelphia); monoclonal anti-MART-1 7c10 (ABCAM); rabbit anti mouse IgG was 
purchased from Dakopatt; polyclonal anti biotin (Polysciences Biovalley). Monoclonal 
anti-LAMP1 (BD Biosciences). Chloroquine, MG132 and Epoxomycin (SIGMA Aldrich); 
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DAMP (3-(2,4-dinitroanilino)-3’-amino-N-methyldipropylamine) (Invitrogen). Bovine 
Serum Albumin coupled to 5 nm gold particles (BSAG) and Protein A Gold conjugates 
were purchased from Cell Microscopy Center, Utrecht The Netherlands.  
Cloning of OA1-tagged constructs 
The human OA1 coding sequence was amplified by polymerase chain reaction 
(PCR) by using Pfu high fidelity DNA polymerase (Promega) and the following 
primers containing EcoRI and XhoI restriction sites: 
OA1fw:CGGAATTCATGACCCAGGCAGGCCGG;OA1rw:CCGCTCGAGTCACACCTGGACAC
GGAAG. The PCR product was digested by EcoRI and XhoI and subsequently cloned 
into EcoRI/XhoI-digested pcDNA3-flag vector to express OA1 with a Flag-tag at the 
C-terminus. The same PCR product was also cloned into pEGFP-N1 vector 
(Invitrogen) to express OA1 with an EGFP-tag at the C-terminus. 
Quantitative Real time-PCR  
Total RNA was extracted from siRNAs and control transfected MNT-1 cells 
using RNeasy MiniKit (Quiagen) according to the manufacturer’s instructions. The 
same amount of cDNA was synthesized using Superscript II (Invitrogen) and random 
primers. Real time PCR was carried out with the GeneAmp 7000 Sequence Detection 
System (Applied Biosystem). The RT-PCR reaction was performed using cDNA, 12.5 
µl SYBR green master mix (Applied Biosystem) and 400 nM primers for each gene 
(see list below). Water was added to a final reaction volume of 25 µl. The PCR 
conditions were as follows: preheating at 50°C for 2 min and 95°C for 10 min; 40 
cycles of 15 s at 95°C and 1 min at 60°C.  
Quantification results were expressed in terms of the cycle threshold (Ct). All real-
time qPCR reactions were run in triplicate and the Ct values were averaged from 
three independent samples. Data were normalized to the internal control, the 
reference gene S26. Differences between the mean Ct values of each gene and 
those of the reference gene were calculated as ∆Ct=Ctgene-Ctreference and represented 
as 2-∆Ct.  
 
Sequences of the forward (fw) and reverse (rw) intron-spanning primers used for 
Real-time qPCRs: 
Human S26 fw CCG TGC CTC CAA GAT GAC AA 
Human S26 rw GCA ATG ACG AAT TTC TTA ATG GCC T 
Human OA1 fw CGG AGA TCG GCA GGA CTG AGC AC 
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Human OA1 rw ATA GTG GGG GAT GGC GTG GT 
Human MART-1 fw GAAGGGTTTGATCATCGGGA 
Human MART-1 rw GCATTGGGAACCACAGGTTC 
Human Pmel17-fw CAGCTCAGCCTTCACCATTA 
Human Pmel17 rw AAGTGCTTGTTCCCTCCATC 
 
Immunoprecipitations and Western Blotting 
siRNA treated MNT-1 cells at 80% of confluency and control MNT-1 cells were 
washed in cold PBS and lysed on ice in lysis buffer (50 mM Tris, 150 mM NaCl, 1% 
Triton X-100, 10 mM EDTA, pH 7,2 and protease inhibitor cocktail (Roche 
11836153001). Lysates were then centrifuged at 21,000g for 20 min at 4°C. Protein 
concentrations were determined by Micro BCATM Protein Assay Reagent Kit (Pierce). 
The protein samples were mixed with an equal volume of loading buffer containing 
2% SDS (or 14% SDS for OA1) with 5% β-mercaptoethanol and then boiled for 2 
min (or warmed 30 min at 37° for OA1 protein). For immunoprecipitation protein 
samples were first precleared using protein G agarose beads for 2 hrs at 4°C under 
rotation. Supernatants were collected and incubated with protein G agarose beads 
with 1 µg of rabbit anti-human IgG for 5 hrs at 4°C. To immunoprecipitate OA1, 
supernatants were incubated with 1 µg of anti-OA1 polyclonal antibody O/N at 4°C 
under rotation. As controls, 1 µg of rabbit anti-human IgG was used. After 10 
washes in cold lysis buffer, immunoprecipitated proteins bound to the beads were 
incubated in sample buffer (containing 14% SDS for OA1 protein) and then boiled for 
2 min (warmed 30 min at 37° for OA1 protein). Immunoprecipitated proteins were 
loaded and separated in 8% SDS-PAGE gel to reveal OA1 and in Nupage (4-12%) 
Bis-Tris gels (Invitrogen)  to reveal the other proteins.  
The separated proteins were then transfered to polyvinylidene difluoride membrane 
(Millipore) in XCell IItm Blot Module (Invitrogen) and the membranes were blocked in 
PBS/0.1%Tween-20 (PBS/T) with 5% non-fat dried milk, incubated with primary 
antibody in PBS/T, washed four times in blocking solution, and incubated with 
horseradish peroxidase-conjugated secondary antibody (anti-rabbit or anti-mouse; 
1:10000; Jackson ImmunoResearch Laboratories) followed by washing in PBS/T. 
Visualization of the antibody binding was carried out with ECL Plus Western blotting 
detection system (GE Healthcare) according to the manufacturer’s instruction. Signal 
intensities were quantified with Image J software.  
Melanin assay 
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Cells were disrupted by sonication in 50 mM Tris-HCl, pH 7.4, 2 mM EDTA, 
150 mM NaCl, 1 mM dithiothreitol and protease inhibitors. Pigment was pelleted at 
20,000g for 15 min at 4°C, rinsed once in ethanol/ether (1:1), and dissolved in 2M 
NaOH/ 20% dimethylsulfoxide at 60°C. Melanin content was measured as optical 
density at 492 nm (48). 
Immunofluorescence (IF)  
 Transfected MNT-1 cells on coverslips were rinsed in PBS and fixed for 15min 
in 4% paraformaldehyde/PBS at room temperature (RT). Fixed cells were washed in 
PBS and quenched 10 min in PBS/ 50 mM glycin, saturated in PBS/ 1 mg/ml BSA 
(blocking buffer) and permeabilized in PBS/ 0.05% saponin/ 1 mg/ml BSA 
(incubation buffer, IB). Cells were incubated 1 hr with the primary antibody diluted in 
IB, washed three times in IB and incubated with the corresponding secondary 
antibody Alexa 488- or Alexa 568-conjugated anti-rabbit or anti-mouse secondary 
antibodies (1:200; Molecular probes) for 45 min in IB and washed again. Finally, 
coverslips were mounted in DABCO medium and examined on a Leica Microsystemes 
(Nanterre, France) DM-RXA2 3D deconvolution microscope equipped with a piezo z-
drive (Physik Instrument, Pantin, France) and a 100x1.4NA-PL-APO objective lens for 
optical sectioning. Images are maximum-intensity z projections of 3D image stacks 
acquired using Metamorph software (MDS Analytical Technologies, Sunnyvale, CA) 
through a Coolsnap HQ (Photometrics Coolsnap HQ) cooled CCD-camera except 
images shown in fig 5B-I where single stacks were deconvoluted. 
 Electron Microscopy (EM) 
For conventional EM, cells grown on coverslips were fixed with 2.5% 
glutaraldehyde in 0.1M cacodylate buffer for 24 hrs. After several washes with 0.1M 
cacodylate buffer, the cells were postfixed with 2% OsO4, dehydrated in ethanol, 
and embedded in Epon while on the coverslips. Ultrathin sections were prepared and 
counterstained with uranyl acetate and lead citrate before the observation. For 
quantification, melanosomes were counted on 10 randomly acquired micrographs at 
X5,000 of siOA1 and control MNT1 cells. The area of cell analyzed was determined 
by iTEM software and expressed in square micrometers (160µm2). 
For immunogold labelling, cells were fixed with a mixture of 2%PFA and 0.2% 
glutaraldehyde in 0.1M phosphate buffer, pH 7.4 and processed for 
ultracryomicrotomy as previously described (49).  Ultrathin cryosections were single- 
or double-immunogold labelled with antibodies and protein A coupled to 5 or 10 or 
15-nm gold, as indicated in the legends to the figures. Sections of resin embedded 
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cells and immunogold labeled cryosections were observed under a Philips CM120 
electron microscope (FEI company), equipped with a KeenView camera (Soft 
Imaging System; SIS, Germany). For quantification of OA1 labeling, 500 gold 
particles (endogenous OA1) or 800 (transfected OA1) were counted in randomly 
selected cells profiles of cells in each of two experiments. Tyrp1 and LAMP1 gold 
particles were randomly counted in a total of 80 unpigmented (stage I/II) or 
pigmented (stage III/IV) melanosomes, in two separate experiments. Data are 
presented as mean ± SD.  
Uptake of BSAG and DAMP 
Uptake of the endocytic tracer BSAG and the weak base DAMP (3-(2,4-
dinitroanilino)-3’-amino-N-methyldipropylamine) were performed on living cells 
before fixation and processing as previously reported (9). Uptake of BSAG: cells were 
washed with serum-free DMEM, pulsed for 10 min at 37° with BSAG (OD520nm=5), 
washed with ice-cold medium/2%FBS and the endocytic tracer was chased for 
45min. After washing with ice-cold medium, cells were fixed. Incubation with DAMP: 
cells were washed with serum-free DMEM and incubated with DAMP (30µM) for 15 
min at 37°. Cells were washed with ice-cold medium and then fixed.  
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Legends to Figures 
 
Figure 1.  
Localization of OA1 in MNT-1 cells. Ultrathin cryosections of MNT-1 cells were 
double immunogold labeled with anti-OA1 and anti-Tyrp1 (A and B) or anti-OA1 and 
anti-Pmel17 (C and D) or anti-OA1 and anti-LAMP1 (E). (A) OA1 (PAG 15) is detected 
in the limiting membrane (arrows) and in small intraluminal vesicles (arrowhead) of 
pigmented Tyrp1 (PAG10)- positive melanosomes. (B) Note the presence of OA1 in 
the membrane of vesicles close to melanosomes (arrowhead). (C and D) Pmel17 
(PAG 5)-positive compartments (unpigmented fibrillar melanosomes) show high 
labeling for OA1 (PAG 10) (arrows fig 1C,D). (E) OA1 (PAG10) localizes to the 
limiting membrane of LAMP1 (PAG15) positive lysosomes (arrow) and to the 
membrane of internal vesicles of late endosomes (arrowheads). I, stage I. II, stage 
II. III, stage III. IV, stage IV. I/II, stage I/II. LE, late endosome. Lys, lysosome.  
Bars, 200 nm. (F) Quantification of gold particles labeling OA1 on ultrathin 
cryosections of MNT-1 cells. Results are presented as the percentage of the total 
number of gold particles for OA1 (PAG 10) in the distinct morphologically defined 
compartments. The highest labeling for OA1 is observed in stage II premelanosomes 
(24%).  
  
Figure 2. 
Inactivation of OA1 affects melanosome number, melanosome size and 
composition. MNT-1 cells were transfected with control (Ctrl) non-targeting siRNA 
or 3 different siRNAs targeting OA1 (siRNA#1,#2,#3) (A) Cell harvested five days 
after siRNA transfection were analyzed by real time qPCR. Real time qPCR reactions 
were performed in triplicate and averaged. Y-axis: 2(-dCT) value represents differences 
between the mean Ct (cycle threshold) values of tested genes (OA1) and those of 
reference gene (S26). 2(-dCT) values are significantly lower in MNT-1 cells interfered 
with oligo siOA1#3 and siOA1#2 (reduction of OA1 mRNA levels: 15% siRNA #1, 
78% siRNA #2, 95% siRNA #3) than in the control.  (B) Cells treated with OA1 or 
control siRNAs were analyzed by immunoblotting with the polyclonal anti-OA1 
antibody and anti β-tubulin. OA1 appears as a doublet of 45-48kDa and a band at 
60kDa corresponding to different patterns of glycosylation. The extra band at 65KD 
(asterisk) is a non-specific. OA1 protein levels are significantly reduced in cells 
interfered with siOA1#3 and siOA1#2. (C,D) OA1 distribution was analyzed by 
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immunofluorescence, using the polyclonal anti-OA1 antibody in control and in siOA1 
treated cells (siOA1#2 or siOA1#3).   OA1 expression is clearly reduced in most 
siOA1 treated cells. (E,F) Bright field images show the reduction of pigmentation in 
siOA1 treated cells, as compared to control cells. (G) Evaluation of melanin content 
in OA1 depleted cells shows a 50% decrease and as shown in Inset the decrease in 
pigmentation is visible in cell pellets  (same number of OA1 depleted and control 
cells diluted in the same volume). Y-axis: Percentage (%) of Melanin content 
normalized to the control (assumed as 1%). (H,I) Cells treated with OA1 or control 
siRNAs were analyzed by conventional EM. Note the different stages of melanosomes 
in control cells (I,II,III,IV) (H) OA1 depleted cells display only few pigmented, 
normal sized melanosomes (IV) and show several “enlarged” organelles with 
different morphological features: melanosomal structures with disorganized fibrils 
(arrowhead), with melanin deposits (arrows) and aberrant mixed compartments 
(asterisk) containing fibrillar striations and melanin pigment (I). (L) Histogram 
representing the number of melanosomes (stage II+III+IV) per area (160µm2) in 
control and siOA1 treated cells. Bars, 200 nm. (K) Number of different stage 
melanosomes in control and siOA1 cells. In siOA1 cells melanosomes were 
distinguished between normal (organized fibers, normal size), aberrant melanosomes 
(fibrils disorganized, bigger size) and mixed melanosomes. Melanosomes were 
counted on 10 randomly acquired micrographs at X5,000 of siOA1 and control MNT1 
cells. The area of cell analyzed was determined by iTEM software and expressed in 
square micrometers (160µm2). 
 
Figure 3.  
Localization of Tyrp1 and LAMP1 in OA1 depleted cells. Ultrathin cryosections 
of MNT-1 cells treated with control (Ctrl; A,C,E) or OA1 siRNA (siOA1; B,D,F,G,H) 
were double immunogold labeled for Tyrp1 (PAG10) and Pmel17 (PAG5)(A,B) or 
Tyrp1 (PAG10) and LAMP1 (PAG15)(C,D,E,F,G,H). Labeling for Tyrp1 is observed at 
the limiting membrane of mature pigmented melanosomes (A, arrows) but not in 
Pmel17 positive premelanosomes (arrowhead). Note a lysosome highly labeled for 
LAMP1 (C, arrow). (B) OA1 depleted cells show aberrant premelanosomes with 
disorganized fibrils and those are labeled for both Tyrp1 (arrows) and Pmel17 
(arrowhead). (D-G) Note the labeling for LAMP1 on the membrane of melanosomes 
and pigmented enlarged compartments in siOA1 treated cells as compared to control 
(arrows). (H) LAMP1 was present also in Tyrp1 positive vacuolar structures 
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generated in OA1 depleted cells (arrows inset). II, stage II. IV, stage IV. Bars 
200nm. (I) Western blot analysis of lysates of cells treated with control (Ctrl) and 
OA1 (siOA1) siRNAs using anti-Tyrp1 or anti-LAMP1 antibodies and anti-β-tubulin as 
a loading control. In siOA1 treated cells the expression of Tyrp1 is slightly increased 
whereas LAMP1 levels remain unchanged. 
 
Table 1. 
Quantitative analysis of Tyrp1 and LAMP1 distribution in different melanosomal 
stages in siOA1 and control cells. 
Tyrp1 and LAMP1 gold particles were randomly counted in a total of 80 unpigmented 
(stage I/II) or pigmented (stage III/IV) melanosomes, in two separate experiments. 
Data are presented as mean ± SD. N, number of gold particles. % percentage of 
gold particles. In siOA1 cells melanosomes were distinguished between normal 
(organized fibers, normal size) and aberrant melanosomes (fibrils disorganized, 
bigger size). 
 
Figure 4.  
MART-1 depletion affects Pmel17 processing and melanosome biogenesis. 
(A) Western blot analysis of TX-soluble fraction extracted from cells treated with 
control (Ctrl) and OA1 (siO) siRNAs using anti-HMB45 (Aa) or pep13h (Ac) antibody 
directed against the processed forms and the C-terminal of Pmel17 respectively and 
anti-β-tubulin as a loading control.  Note the accumulation of Malpha (Mα) fragment 
and the reduction of MalphaC (MαC) fragment in siOA1 lysates (Aa, arrows). TX-
insoluble pellets (enriched in Mα, the luminal domain fragment of Pmel17) from 
siOA1 and control cells were re-extracted in TX lysis buffer containing 8M Urea at 
60° and analysed by western blot using anti-HMB45 (Pmel17; Mα and MαC) antibody 
(Ab). The accumulation of Malpha (Mα) fragment and the reduction of MalphaC 
(MαC) are maintained. (B) Western blot analysis of lysates from cells treated with 
control (Ctrl) and MART-1 (siM) siRNAs using anti-MART-1 (Ba), anti-HMB45 (Bb) or 
pep13h (Bc) antibody against the processed forms and the C-terminal of Pmel17 
respectively and anti-β-tubulin as a loading control.  Note the accumulation of 
Malpha (Mα) fragment and the reduction of MalphaC (MαC) fragment in siMART-1 
lysates (Bb, arrows). (C,D,E,F) Ultrathin cryosections of control and siMART-1 treated 
MNT-1 cells were single immunogold labeled for Pmel17 (HMB50; PAG 5) (C and D) 
or double immunogold labeled for Tyrp1 (PAG 10) and Pmel17 (HMB50; PAG 5) (E 
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and F). MART-1 depleted cells display aberrant enlarged compartments with a mixed 
content of Pmel17 positive fibrils and electron dense pigment (arrow in D). As shown 
in (F) in MART-1 depleted cells, Tyrp1 localizes to Pmel17 positive unpigmented 
melanosomal compartments. II, stage II. IV, stage IV. Bars 200 nm. 
 
Figure 5.  
OA1 and MART-1 co immunoprecipitate and co localize in Golgi and TGN 
(A) MNT-1 cell lysates were immunoprecipitated with polyclonal anti-OA1 (IP OA1) or 
anti rabbit IgG (IP IgG rabbit) antibody. Immunoprecipitates were fractionated by 
SDS-PAGE and immunoblotted with anti-MART-1, Tyrp1 or OA1 antibody as indicated 
on the right of each panel. The arrow indicates a specific band detected by anti-
MART-1 antibody in OA1-immunoprecipitates.  
(B,C,D) MNT-1 cells were analyzed by immunofluorescence and deconvolution after 
double labeling for OA1 (B; green) and MART-1 (C; red). Overlap of the two images 
is shown in D and the phase (blue pseudocolored melanosomes) is shown in E. 
Magnified insets are also shown (F,G,H,I). Arrows indicate colocalization between 
OA1 and MART-1. (J,K,L) Ultrathin cryosections of MNT-1 cells were double 
immunogold labeled for OA1 and MART-1 and analyzed by EM. OA1 and MART-1 are 
detected in the Golgi and in associated vesicles (J, arrows), at the cytosolic side of 
small endosomes (K, arrow) and in multivesicular compartments (L, arrow). TGN, 
Trans Golgi Network. IV, stage IV. Bars 200 nm. 
 
Figure 6 
Depletion of MART-1 affects OA1 stability. MNT-1 cells were treated with 
control (Ctrl) siRNA or siRNA targeting MART-1 (siMART-1). (A-H) 
Immunofluorescence analysis of control (A,B,C,D) and siMART-1 cells (E,F,G,H) 
stained with anti-MART-1 (red) and anti-OA1 (green) antibodies. MART-1 depleted 
cells (arrow) show a clear decrease in OA1 labeling. Phase is shown in D and H. (I) 
Real Time quantitative PCR of MART-1 and OA1, in siMART-1 (siMART-1) and control 
(Ctrl) MNT1 cells. Note that MART-1 RNA is significantly decreased (94%) and OA1 
RNA does not significantly change in siMART1 cells. Y-axis: 2(-dCT) value represents 
differences between the mean Ct (cycle threshold) values of tested genes and those 
of reference gene (S26). (J) Western blot analysis of lysates of cells treated with 
control (Ctrl) and MART-1 (siM) siRNAs using anti-MART-1 or anti-OA1 antibody and 
anti-β-tubulin as a loading control.  Note the depletion of MART-1 (90%) and the 
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reduction of OA1 protein (85%) in cells treated with MART-1 siRNA. Arrows point to 
the specific forms of OA1 (60 kDa and doublet 45-48 kDa). (K) Western blot analysis 
of control (Ctrl) and siMART-1 (siM) cells, treated with Chloroquine 200µM (Chlor, 
lysosome inhibitor)(Ka) or MG132 50 µM (MG132, proteasome inhibitor)(Kb) or 
Epoxomycin 10 µM (Epox, specific proteasome inhibitor)(Kc) for 5hrs, 5 days after 
siRNAs transfection. Control cells treated with Chloroquine show an increase in OA1 
as compared to untreated control cells. OA1 levels increase also in siMART-1 cells 
treated with Chloroquine, as compared to untreated siMART-1. Note also the 
increase of OA1 in siMART-1 cells treated with MG132 and Epoxomycin as compared 
to the untreated inactivated cells. Arrows point to the specific forms of OA1 (60 kDa 
and doublet 45-48 kDa). Graphs shows signal intensity of OA1 normalized to β-
tubulin in the different conditions of two separate experiments. Data are expressed 
as arbitrary units and presented as mean ± SD.  
 
 
 
Supplementary Figures 
 
Figure S1. 
Localization of OA1-Flag in transfected MNT-1 cells. Ultrathin cryosections of 
MNT-1 cells transfected with OA1-Flag construct were double immunogold labeled 
with anti-Flag (OA1) and anti-Tyrp1 (A and B) or with anti-Flag (OA1) and anti-
Pmel17 (C). (A and B) OA1-Flag (PAG 15) is present at the limiting membrane of 
Tyrp1-positive (PAG 10) pigmented melanosomes (arrows, A), in small intraluminal 
vesicles that are also labeled for Tyrp1 (arrowhead, A, B) and in intracellular small 
vesicles closed to melanosomes (asterisk, B). Note the presence of large electron 
lucent OA1-Flag positive membrane vacuoles (350 nm) labeled for Tyrp1 that localize 
at the proximity of melanosomes (asterisks, A). (C). OA1-Flag (PAG15) localizes to 
stage IV pigmented mature melanosomes (arrows) while stage II unpigmented 
premelanosomes do not show consistent labeling. Bars, 200 nm. (D) Quantitative 
analysis of the distribution of OA1-Flag in MNT-1 transfected cells. Results are 
presented as the percentage of the total number of counted gold particles for OA1 
(PAG 15) in the distinct morphologically defined compartments in MNT-1 cells. The 
highest labeling for OA1 is observed in stage IV premelanosomes (23%).  
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Figure S2. 
Aberrant melanosomes are generated in OA1 depleted MNT1 and in OA1 
knock out mouse melanocytes. OA1 siRNA targeted or not targeted human 
MNT1 (siOA1; A,B,C) and OA1 Knock-out (melan-OA1-/-) or wild type (melan-a) 
mouse melanocytes (D,E) were analyzed by conventional EM (A,B,D,E) or after 
double immunogold labeling for Tyrp1 (PAG 15) and Pmel17 (PAG 5) on ultrathin 
cryosections (C). (A) Electron micrograph showing a siOA1 targeted cell (defined on 
the base of the typical phenotype) close to a siOA1 not targeted cell. Melanosomes 
in the siOA1 targeted cell display disorganized luminal fibrils and are 3 times bigger 
than in the not targeted cell (arrows). I, stage I. II, stage II. III, stage III. IV, stage 
IV. Bar: 1 µm. (B) OA1 depleted cells show aberrant melanosome displaying electron 
dense pigment surrounded by fibrils characteristic of immature premelanosomes. 
These fibrils are labeled for Pmel17 (arrows, C). Bars 200 nm. (D,E) Electron 
micrographs of regions of the cytoplasm of OA1 Knockout (melan-Oa1-/-; E) and wild 
type (melan-a; D) melanocytes. Arrows indicate aberrant pigmented compartments 
with a mixed content in OA1 Knockout cells.  Insets are 2,5X magnification of areas 
showing representative melanosomes. II, stage II. III, stage III. IV, stage IV. Bars 
200nm. 
 
Figure S3 
(A,B) Control (Ctrl) or OA1 siRNA (siOA1)  treated MNT1 cells were pulsed with BSAG 
(5nm) for 10 min and the endocytic tracer was chased at 37°C for 45 min. BSAG is 
present in MVBs (arrowheads, A-B) located close to melanosomes labeled for Tyrp1 
(arrows, A-B ). The enlarged melanosomal organelles in siOA1 cells were not 
accessed by the BSAG (B). (C,D) Control (Ctrl) and OA1 depleted (siOA1) MNT1 cells 
were incubated with DAMP for 15 min at 37°C and then fixed, processed and double 
immunogold labeled for Tyrp1 (PAG10) and DAMP, visualized with anti-DNP antibody 
(PAG 5). The weak base DAMP accumulates primarily in stage II melanosomes while 
stage IV melanosomes show less labeling. The enlarged melanosomal organelles 
(arrow, D) in siOA1 cells appear to be correctly acidified. III, stage III. II/III, stage 
II/III. IV, stage IV. Bars 200 nm. 
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(A) Real Time quantitative PCR of OA1, Pmel17 and MART-1 and in siOA1 treated 
(siOA1) and control (Ctrl) MNT1 cells. Y-axis: 2(-dCT) value represents differences 
between the mean Ct (cycle threshold) values of tested genes and those of reference 
gene (S26). Pmel17 and MART-1 RNA levels do not change in siOA1 cells. (B) 
Western blot analysis of lysates of cells treated with control (Ctrl) and OA1 (siOA1) 
siRNAs using anti-MART-1 and anti-β-tubulin as a loading control. MART-1 does not 
significatively change in siOA1 treated cells vs control.  
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Figure 3 
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Figure 4 
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Figure 5 
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Supplementary Figure 1 
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Supplemntary Figure 2 
Page 40 of 42Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 41 
 
Supplementary Figure 3 
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Supplementary Figure 4 
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